Palisade Bio Promotes J.D. Finley to Chief Executive Officer
June 01, 2023 08:45 ET
|
Palisade Bio, Inc.
Carlsbad, CA, June 01, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company advancing therapies for acute and chronic...
Aridis Pharmaceuticals Receives Nasdaq Notice on Late Filing of its Form 10-Q
May 25, 2023 16:05 ET
|
Aridis Pharmaceuticals, Inc.
LOS GATOS, Calif., May 25, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) (“Aridis” or the “Company”), a biopharmaceutical company, announced today that it received a notice...
Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Addition to the Russell 2000® Index
May 25, 2023 08:01 ET
|
Ocean Biomedical, Inc.
Providence, RI, May 25, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical (NASDAQ: OCEA) announced today that it is expected to be added to the Russell 2000® Index, effective after the U.S. market opens on...
Palisade Bio’s LB1148 Two Ongoing Clinical Trials Expecting Topline Data Readouts
May 24, 2023 08:45 ET
|
Palisade Bio, Inc.
Company approaching Phase 2 topline data readout for prevention of post-surgical abdominal adhesions Continued momentum with execution of ongoing dose optimization study with 25% enrollment...
Timber Pharmaceuticals Provides Business Update and Announces First Quarter 2023 Financial Results
May 15, 2023 16:15 ET
|
Timber Pharmaceuticals
- Timber has now Enrolled Over 60% of Patients for Pivotal TMB-001 Phase 3 ASCEND Clinical Trial - WARREN, NJ, May 15, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc....
Aeterna Zentaris Announces Virtual 2023 Meeting of Shareholders
May 15, 2023 16:05 ET
|
Aeterna Zentaris Inc
TORONTO, ONTARIO, May 15, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing...
Palisade Bio Reports First Quarter 2023 Financial Results
May 12, 2023 08:05 ET
|
Palisade Bio, Inc.
Company has sufficient cash expected to fund operations through 2024 Carlsbad, CA, May 12, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a...
Palisade Bio Announces Enrollment and Dosing of First Patient in LB1148 Dose Optimization Study
May 11, 2023 09:05 ET
|
Palisade Bio, Inc.
Study designed to determine if a different dosing protocol for all indications might enhance the risk profile of LB1148 while simultaneously providing efficacy Company expects enrollment to be...
Aridis Pharmaceuticals Receives Nasdaq Notice on Late Filing of its Form 10-K
April 26, 2023 12:15 ET
|
Aridis Pharmaceuticals, Inc.
LOS GATOS, Calif., April 26, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) (“Aridis” or the “Company”), a biopharmaceutical company, announced today that it received a notice...
Vallon Pharmaceuticals Adjourns Special Meeting of Stockholders Until April 20, 2023
April 12, 2023 16:05 ET
|
Vallon Pharmaceuticals Inc.
Board of Directors unanimously recommend Vallon stockholders to vote “FOR” all proposals outlined in the Company’s definitive Proxy Statement (the “Proxy”) in order to close the proposed merger with...